IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model

13Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

IRX-2, a natural cytokine biological with multiple components, has been used in preclinical and clinical studies to promote antitumor activity of T lymphocytes. To define cellular mechanisms responsible for antitumor effects of IRX-2, its ability to induce effector T cells (Teff) was examined in a model simulating the tumor microenvironment. An in vitro model containing conventional CD4 +CD25 - cells co-cultured with autologous immature dendritic cells, irradiated tumor cells, and cytokines was used to study differentiation and expansion of regulatory T cells (Treg) and Teff in the presence and absence of IRX-2. Phenotype, suppressor function, signaling, and cytokine production were serially measured using flow cytometry, Western blots, CFSE-based suppressor assays, and Luminex-based analyses. The presence of IRX-2 in the co-cultures promoted the induction and expansion of IFN- γ +Tbet + Teff and significantly (p∈

Cite

CITATION STYLE

APA

Schilling, B., Harasymczuk, M., Schuler, P., Egan, J. E., & Whiteside, T. L. (2012). IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. Journal of Molecular Medicine, 90(2), 139–147. https://doi.org/10.1007/s00109-011-0813-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free